title: Impact of tumor microenvironment on oncolytic viral therapy.
abstract: Interactions between tumor cells and their microenvironment have been shown to play a very significant role in the initiation, progression, and invasiveness of cancer. These tumor-stromal interactions are capable of altering the delivery and effectiveness of therapeutics into the tumor and are also known to influence future resistance and re-growth after treatment. Here we review recent advances in the understanding of the tumor microenvironment and its response to oncolytic viral therapy. The multifaceted environmental response to viral therapy can influence viral infection, replication, and propagation within the tumor. Recent studies have unveiled the complicated temporal changes in the tumor vasculature post-oncolytic virus (OV) treatment, and their impact on tumor biology. Similarly, the secreted extracellular matrix in solid tumors can affect both infection and spread of the therapeutic virus. Together, these complex changes in the tumor microenvironment also modulate the activation of the innate antiviral host immune response, leading to quick and efficient viral clearance. In order to combat these detrimental responses, viruses have been combined with pharmacological adjuvants and "armed" with therapeutic genes in order to suppress the pernicious environmental conditions following therapy. In this review we will discuss the impact of the tumor environment on viral therapy and examine some of the recent literature investigating methods of modulating this environment to enhance oncolysis.
authors.affiliation: Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center, Columbus, OH 43210, United States.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Wojton
authors.forename: Balveen
authors.initials: B
authors.lastname: Kaur
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005109:Extracellular Matrix / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D007113:Immunity, Innate; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000235:genetics / Q000276:immunology / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
references.citation: Mol Ther. 2007 Nov;15(11):1982-90
references.pmid: 17653103
references.citation: Nat Clin Pract Oncol. 2007 Feb;4(2):101-17
references.pmid: 17259931
references.citation: Gene Ther. 2005 Jun;12(11):911-7
references.pmid: 15690061
references.citation: J Immunol. 2008 May 1;180(9):6018-26
references.pmid: 18424722
references.citation: J Virol. 2000 May;74(10):4765-75
references.pmid: 10775615
references.citation: Mol Ther. 2008 Jun;16(6):1041-7
references.pmid: 18388912
references.citation: Anticancer Agents Med Chem. 2006 Sep;6(5):407-28
references.pmid: 17017851
references.citation: Hum Gene Ther. 2000 Nov 1;11(16):2219-30
references.pmid: 11084679
references.citation: Cell Cycle. 2009 Jul 15;8(14):2194-7
references.pmid: 19502787
references.citation: J Immunol. 2009 Feb 1;182(3):1763-9
references.pmid: 19155526
references.citation: Mol Ther. 2001 May;3(5 Pt 1):697-707
references.pmid: 11356075
references.citation: Circ Res. 2005 Jan 7;96(1):15-26
references.pmid: 15637304
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3933-41
references.pmid: 18559615
references.citation: J Virol. 2004 Sep;78(17):8960-70
references.pmid: 15308693
references.citation: J Virol. 2005 Aug;79(16):10589-600
references.pmid: 16051851
references.citation: Cancer Res. 2007 Oct 1;67(19):9398-406
references.pmid: 17909049
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14981-6
references.pmid: 18815361
references.citation: J Virol. 2001 Oct;75(20):9828-35
references.pmid: 11559816
references.citation: Chem Rev. 2009 Jul;109(7):3125-40
references.pmid: 19462957
references.citation: Mol Ther. 2008 Jan;16(1):146-53
references.pmid: 18071337
references.citation: Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5247-51
references.pmid: 8202476
references.citation: J Gen Virol. 2008 Jan;89(Pt 1):1-47
references.pmid: 18089727
references.citation: Hum Gene Ther. 2005 Jun;16(6):765-78
references.pmid: 15960607
references.citation: Cancer Chemother Pharmacol. 2009 Nov;64(6):1201-10
references.pmid: 19308409
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9578-83
references.pmid: 15210966
references.citation: Proc Natl Acad Sci U S A. 1998 May 26;95(11):6355-60
references.pmid: 9600969
references.citation: J Virol. 2010 Jan;84(2):856-66
references.pmid: 19906926
references.citation: Neoplasia. 2004 Nov-Dec;6(6):725-35
references.pmid: 15720798
references.citation: Mol Ther. 2005 Nov;12(5):789-802
references.pmid: 15925544
references.citation: Mol Ther. 2010 Feb;18(2):285-94
references.pmid: 19844198
references.citation: Mol Ther. 2004 Nov;10(5):938-49
references.pmid: 15509511
references.citation: J Natl Cancer Inst. 2006 Oct 18;98(20):1482-93
references.pmid: 17047197
references.citation: Gene Ther. 2010 Feb;17(2):190-201
references.pmid: 19907500
references.citation: Cancer Biol Ther. 2006 Jan;5(1):48-53
references.pmid: 16294031
references.citation: Gene Ther. 2009 Aug;16(8):1009-20
references.pmid: 19440223
references.citation: Cancer Res. 2007 Jan 15;67(2):440-4
references.pmid: 17234749
references.citation: Mol Cancer Ther. 2007 Oct;6(10):2728-36
references.pmid: 17938266
references.citation: Mol Ther. 2007 Mar;15(3):588-97
references.pmid: 17245355
references.citation: Clin Cancer Res. 2009 Apr 15;15(8):2777-88
references.pmid: 19351762
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6505-14
references.pmid: 18927290
references.citation: Recent Pat CNS Drug Discov. 2009 Jan;4(1):1-13
references.pmid: 19149710
references.citation: Hum Gene Ther. 2003 Mar 20;14(5):425-33
references.pmid: 12691608
references.citation: Glia. 2003 Apr 1;42(1):77-88
references.pmid: 12594739
references.citation: Cancer Res. 2006 Mar 1;66(5):2509-13
references.pmid: 16510565
references.citation: Gene Ther. 2006 Jun;13(12):986-90
references.pmid: 16525485
references.citation: J Clin Invest. 2002 Oct;110(8):1105-11
references.pmid: 12393846
references.citation: Clin Cancer Res. 2009 Jan 15;15(2):561-9
references.pmid: 19147761
references.citation: Mol Ther. 2008 Aug;16(8):1382-91
references.pmid: 18545226
references.citation: Curr Gene Ther. 2009 Oct;9(5):341-55
references.pmid: 19860649
references.citation: Mol Ther. 2007 Sep;15(9):1686-93
references.pmid: 17579581
references.citation: Mol Ther. 2008 Oct;16(10):1665-73
references.pmid: 18665155
references.citation: Curr Mol Med. 2003 Nov;3(7):643-51
references.pmid: 14601638
references.citation: Nat Med. 2004 Feb;10(2):145-7
references.pmid: 14745444
references.citation: Mol Ther. 2009 Jan;17(1):199-207
references.pmid: 18957964
references.citation: Gene Ther. 2010 Feb;17(2):202-16
references.pmid: 19829315
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12915-20
references.pmid: 19617539
references.citation: Mol Cancer Res. 2007 Jul;5(7):655-65
references.pmid: 17634421
references.citation: J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81
references.pmid: 18042934
references.citation: Curr Cancer Drug Targets. 2007 Mar;7(2):181-9
references.pmid: 17346110
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12873-8
references.pmid: 16908838
references.citation: Science. 2008 Apr 4;320(5872):38-41
references.pmid: 18388269
references.citation: Mol Ther. 2008 May;16(5):879-85
references.pmid: 18388918
references.citation: Annu Rev Immunol. 2001;19:65-91
references.pmid: 11244031
references.citation: Nat Rev Cancer. 2003 Jun;3(6):401-10
references.pmid: 12778130
references.citation: Mol Ther. 2007 Feb;15(2):279-86
references.pmid: 17235305
references.citation: Mol Ther. 2009 Jan;17(1):51-6
references.pmid: 18957963
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: Leukemia. 2017 Dec;31(12):2791-2798
references.pmid: 28439108
references.citation: Mol Ther. 2008 Sep;16(9):1546-55
references.pmid: 18648350
references.citation: Cancer Res. 2000 May 1;60(9):2497-503
references.pmid: 10811131
references.citation: Gene Ther. 2005 Jun;12(11):902-10
references.pmid: 15690062